Dashboard Market News Pricing Contact Us
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in

Runben Biotechnology Co Ltd
SSE:603193

Watchlist Manager
Runben Biotechnology Co Ltd Logo
Runben Biotechnology Co Ltd
SSE:603193
Watchlist
Price: 19.14 CNY -3.92% Market Closed
Market Cap: ¥7.7B
Write Note Create Alert Ask AI

Wall St Price Targets

Price Targets Summary
Runben Biotechnology Co Ltd

Wall Street analysts forecast Runben Biotechnology Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Runben Biotechnology Co Ltd is 32.41 CNY with a low forecast of 31.31 CNY and a high forecast of 34.17 CNY.

Lowest Forecast
Wall Street Target
¥31.31
64% Upside
Average Forecast
Wall Street Target
¥32.41
69% Upside
Highest Forecast
Wall Street Target
¥34.17
79% Upside
Lowest Forecast
Price Target
31.31 CNY
64% Upside
Average Forecast
Price Target
32.41 CNY
69% Upside
Highest Forecast
Price Target
34.17 CNY
79% Upside
Runben Biotechnology Co Ltd Competitors:
Price Targets

Revenue
Forecast

22% / Year
Past Growth
19% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss
22% / Year
Past Growth
19% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss

Over the last 2 years, the compound annual growth rate for Revenue has been 22%. The projected CAGR for the next 3 years is 19%.

What are analyst estimates?

Gross Profit
Forecast

24% / Year
Past Growth
20% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss
24% / Year
Past Growth
20% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss

Over the last 2 years, the compound annual growth rate for Gross Profit has been 24%. The projected CAGR for the next 2 years is 20%.

What are analyst estimates?

Operating Income
Forecast

15% / Year
Past Growth
21% / Year
Estimated Growth
Estimates Accuracy
-6%
Average Miss
15% / Year
Past Growth
21% / Year
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Over the last 2 years, the compound annual growth rate for Operating Income has been 15%. The projected CAGR for the next 3 years is 21%.

What are analyst estimates?

Pre-Tax Income
Forecast

16% / Year
Past Growth
19% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
16% / Year
Past Growth
19% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Over the last 2 years, the compound annual growth rate for Pre-Tax Income has been 16%. The projected CAGR for the next 3 years is 19%.

What are analyst estimates?

Net Income
Forecast

18% / Year
Past Growth
19% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
18% / Year
Past Growth
19% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 2 years, the compound annual growth rate for Net Income has been 18%. The projected CAGR for the next 3 years is 19%.

What are analyst estimates?

Continue Research

Summary
intrinsic value, competitors valuation, and company profile.
DCF Valuation
stock valuation using Discount Cash Flow valuation method.
Relative Valuation
stock valuation using valuation multiples.
Wall St Estimates
price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is Runben Biotechnology Co Ltd's stock price target?
Price Target
32.41 CNY

According to Wall Street analysts, the average 1-year price target for Runben Biotechnology Co Ltd is 32.41 CNY with a low forecast of 31.31 CNY and a high forecast of 34.17 CNY.

What is the Revenue forecast for Runben Biotechnology Co Ltd?
Projected CAGR
19%

Over the last 2 years, the compound annual growth rate for Revenue has been 22%. The projected CAGR for the next 3 years is 19%.

What is the Gross Profit forecast for Runben Biotechnology Co Ltd?
Projected CAGR
20%

Over the last 2 years, the compound annual growth rate for Gross Profit has been 24%. The projected CAGR for the next 2 years is 20%.

What is the Operating Income forecast for Runben Biotechnology Co Ltd?
Projected CAGR
21%

Over the last 2 years, the compound annual growth rate for Operating Income has been 15%. The projected CAGR for the next 3 years is 21%.

What is the Pre-Tax Income forecast for Runben Biotechnology Co Ltd?
Projected CAGR
19%

Over the last 2 years, the compound annual growth rate for Pre-Tax Income has been 16%. The projected CAGR for the next 3 years is 19%.

What is the Net Income forecast for Runben Biotechnology Co Ltd?
Projected CAGR
19%

Over the last 2 years, the compound annual growth rate for Net Income has been 18%. The projected CAGR for the next 3 years is 19%.

Back to Top
ALPHA SPREAD
Follow us
Join 357,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.